Brücher B L, Stein H J, Roder J D, Busch R, Fink U, Werner M, Siewert J R
Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der TU München, Ismaninger Strasse 22, D-81675 München, Germany.
Hepatogastroenterology. 2001 May-Jun;48(39):727-32.
BACKGROUND/AIMS: Primary small bowel tumors are rare and the prognosis is generally considered to be poor. Histologically chiefly adenocarcinomas are reported. The surgeon is challenged in their treatment, because of the infrequency, unspecific symptoms and delay in diagnosis. Retrospectively we investigated the surgical therapy, combined morbidity, survival rates and prognostic factors in a large series of primary adenocarcinomas of the small bowel at a single surgical center.
Between 1985 and 1998, 94 patients with a primary tumors of the small bowel (malignant n = 62 [65.9%], benign n = 32 [34.1%]) were operated on. The subgroup of the adenocarcinomas (n = 22) were considered for this study.
The median follow-up is 8.4 years (range: 0.9-14.2 years). Sixteen patients had a follow-up more than 5 years. The main surgical procedure was a small bowel segment resection. Morbidity was 13.6% (only in patients with a duodenal tumors) and the 30-day mortality 5.6%. The estimated 2-year-survival rate was 66%, the 5-year-survival rate 45%. Univariate analysis identified the presence of the residual tumor (R-status) (P = 0.004), tumor stage according to the UICC (P = 0.01), lymph node metastasis (P = 0.007), distant metastasis (P = 0.001), lymphangiosis carcinomatosa (P = 0.001) and vascular invasion (P = 0.0008) as prognostic factors.
A complete macroscopic and microscopic tumor resection including a systemic lymph node dissection has to be the aim of any curative surgical approach in patients with adenocarcinoma of the small bowel.
背景/目的:原发性小肠肿瘤较为罕见,总体预后通常被认为较差。组织学上主要报告为腺癌。由于发病率低、症状不特异以及诊断延迟,外科医生在其治疗上面临挑战。我们回顾性研究了单一外科中心一系列原发性小肠腺癌患者的手术治疗、合并症、生存率及预后因素。
1985年至1998年间,对94例原发性小肠肿瘤患者(恶性62例[65.9%],良性32例[34.1%])进行了手术。本研究纳入腺癌亚组(22例)。
中位随访时间为8.4年(范围:0.9 - 14.2年)。16例患者随访时间超过5年。主要手术方式为小肠节段切除。合并症发生率为13.6%(仅见于十二指肠肿瘤患者),30天死亡率为5.6%。估计2年生存率为66%,5年生存率为45%。单因素分析确定残余肿瘤(R状态)(P = 0.004)、根据国际抗癌联盟(UICC)的肿瘤分期(P = 0.01)、淋巴结转移(P = 0.007)、远处转移(P = 0.001)、癌性淋巴管炎(P = 0.001)和血管侵犯(P = 0.0008)为预后因素。
对于小肠腺癌患者,任何根治性手术方法的目标都必须是进行完整的宏观和微观肿瘤切除,包括系统性淋巴结清扫。